Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
Mengzhao WangJames Chih-Hsin YangPaul L MitchellJian FangD Ross CamidgeWeiqi NianChao-Hua ChiuJianying ZhouYanqiu ZhaoWu-Chou SuTsung-Ying YangViola W ZhuMichael MillwardYun FanWen-Tsung HuangYing ChengLiyan JiangDaniel BrungsLyudmila BazhenovaChee Khoon LeeBo GaoYan XuWei-Hsun HsuLi ZhengPasi A JannePublished in: Cancer discovery (2022)
We report the discovery and early clinical development of sunvozertinib, a potential treatment option for the unmet medical need of EGFRexon20ins NSCLC. This article is highlighted in the In This Issue feature, p. 1599.